The fusion of an immunogenic peptide and the protein transthyretin protects the peptide antigen from proteolytic degradation, optimizes its uptake in local draining lymphatics and reduces its presentation in uninflamed distal lymphoid organs, as shown in mice.
References
Rammensee, H. G., Falk, K. & Rotzschke, O. Annu. Rev. Immunol. 11, 213–244 (1993).
Toes, R. E., Offringa, R., Blom, R. J., Melief, C. J. & Kast, W. M. Proc. Natl Acad. Sci. USA 93, 7855–7860 (1996).
Mehta, N. K. et al. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-020-0563-4 (2020).
Francis, M. J. et al. Proc. Natl Acad. Sci. USA 87, 2545–2549 (1990).
Janssen, R. & Tommassen, J. Int. Rev. Immunol. 11, 113–121 (1994).
Suzue, K. & Young, R. A. J. Immunol. 156, 873–879 (1996).
Mu, X. et al. J. Virol. Methods 228, 84–90 (2016).
Botelho, N. K. et al. Front. Immunol. 10, 294 (2019).
Ishihara, J. et al. Sci. Transl. Med. 9, eaan0401 (2017).
Wille-Reece, U. et al. Proc. Natl Acad. Sci. USA 102, 15190–15194 (2005).
Zom, G. G., Khan, S., Filippov, D. V. & Ossendorp, F. Adv. Immunol. 114, 177–201 (2012).
Kim, S. et al. Nat. Rev. Mater. 4, 355–378 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
P.R. is a member of the scientific advisory board of immatics biotechnologies GmbH. J.A.H. is co-founder of Arrow Immune, Inc., and through his university holds patents in immuno-oncology. The remaining author declares no competing interests.
Rights and permissions
About this article
Cite this article
Romero, P., Donda, A. & Hubbell, J.A. An optimized antigen–protein fusion. Nat Biomed Eng 4, 583–584 (2020). https://doi.org/10.1038/s41551-020-0572-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41551-020-0572-3
- Springer Nature Limited